Crescent Biopharma (CBIO) Enterprise Value (2016 - 2025)
Crescent Biopharma (CBIO) has disclosed Enterprise Value for 11 consecutive years, with -$213.2 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value changed N/A to -$213.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$213.2 million, a N/A change, with the full-year FY2025 number at -$213.2 million, changed N/A from a year prior.
- Enterprise Value was -$213.2 million for Q4 2025 at Crescent Biopharma, down from -$133.3 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$5.6 million in Q1 2025 to a low of -$213.2 million in Q4 2025.
- A 5-year average of -$73.0 million and a median of -$59.1 million in 2022 define the central range for Enterprise Value.
- Biggest YoY gain for Enterprise Value was 82.11% in 2025; the steepest drop was 825.45% in 2025.
- Crescent Biopharma's Enterprise Value stood at -$90.3 million in 2021, then surged by 46.96% to -$47.9 million in 2022, then rose by 12.7% to -$41.8 million in 2023, then soared by 65.54% to -$14.4 million in 2024, then plummeted by 1380.56% to -$213.2 million in 2025.
- Per Business Quant, the three most recent readings for CBIO's Enterprise Value are -$213.2 million (Q4 2025), -$133.3 million (Q3 2025), and -$5.6 million (Q1 2025).